STOCK TITAN

Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Xilio Therapeutics, a biotechnology firm specializing in immuno-oncology therapies, announced that CEO René Russo will speak at Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET. The live presentation will be available on the company's website, with a replay accessible for 30 days post-event. Xilio is focused on developing tumor-activated therapies aimed at improving cancer treatment outcomes while minimizing side effects. Their innovative approach utilizes proprietary technology to target anti-tumor activity specifically within the tumor microenvironment, with multiple programs currently in clinical and preclinical stages.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi’s 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 9:00 a.m. ET.

A live webcast of the presentation can be accessed under “Events & Presentations” in the Investors & Media section of the Xilio Therapeutics website at https://ir.xiliotx.com/. A replay of the webcast will be archived on the website for 30 days following the presentation.

About Xilio Therapeutics

Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to build a pipeline of novel, tumor-activated molecules, including cytokines and other biologics, which are designed to optimize their therapeutic index and localize anti-tumor activity within the tumor microenvironment. Xilio is currently advancing multiple programs for tumor-activated I-O treatments in clinical development, as well as programs in preclinical development. Learn more by visiting www.xiliotx.com and follow us on Twitter (@xiliotx) and LinkedIn (Xilio Therapeutics, Inc.).

This press release contains hyperlinks to information that are not deemed to be incorporated by reference in this press release.

For Investor Inquiries:

Melissa Forst
Argot Partners
xilio@argotpartners.com

For Media Inquiries: 

Julissa Viana
Vice President, Corporate Communications
media@xiliotx.com


FAQ

What is Xilio Therapeutics' participation in Citi’s 2023 Virtual Oncology Leadership Summit?

Xilio Therapeutics' CEO René Russo will participate in Citi’s 2023 Virtual Oncology Leadership Summit on February 23, 2023, at 9:00 a.m. ET.

How can I access the live presentation from Xilio Therapeutics?

The live presentation can be accessed under the 'Events & Presentations' section on Xilio Therapeutics' website.

What are tumor-activated therapies being developed by Xilio Therapeutics?

Xilio Therapeutics is developing tumor-activated immuno-oncology therapies that aim to enhance cancer treatment efficacy with reduced systemic side effects.

Where can I find updates about Xilio Therapeutics and their therapies?

Updates can be found on Xilio Therapeutics' official website and their social media channels, including Twitter and LinkedIn.

What is the ticker symbol for Xilio Therapeutics?

The ticker symbol for Xilio Therapeutics is XLO.

Xilio Therapeutics, Inc.

NASDAQ:XLO

XLO Rankings

XLO Latest News

XLO Stock Data

38.78M
25.97M
40.92%
33.5%
0.9%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM